Skip to content
All Podcasts – Lifestyle
Author:
Pluristyx, Inc.
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
July 6, 2026
Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership
June 16, 2026
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
May 1, 2026
Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology
April 7, 2026
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
March 17, 2026